Genevieve Meier

Applied Physical Sciences (United States) — United States

Medicine · Health Sciences

15h-index1.2kcitations85works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Influenza Virus Research Studies(25), Respiratory viral infections research(15), Hepatocellular Carcinoma Treatment and Prognosis(13), CAR-T cell therapy research(9), Vaccine Coverage and Hesitancy(8)

Publications84 total

Systematic Literature Review of Characteristics Associated with Safety and Healthcare Resource Utilization Outcomes in Various Settings of Care for Chimeric Antigen Receptor T-cell Therapy
Transplantation and Cellular Therapy·2026Open Access
Estimating the Survival Impact of Not Receiving CAR T-cell (CAR T) Therapy When Eligible in Patients with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) in the United States (US)
Transplantation and Cellular Therapy·2026Open Access
Inpatient Versus Outpatient Administration of CAR T-cell Therapy in relapsed/refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Real-World 30- and 60-Day Costs and Resource Utilization
Transplantation and Cellular Therapy·2026
EE188 Cost Trends for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management in Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) Treatment With Axicabtagene Ciloleucel (Axi-cel) in the US
Value in Health·2025
Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US)
Blood·2025Open Access
Real-world healthcare resource utilization (HCRU) following CAR T-cell therapy in US patients treated in newly authorized treatment centers
Blood·2025
Outcomes of inpatient and outpatient chimeric antigen receptor T-cell therapy (CAR T) in newly authorized treatment centers (ATCs) in the United States (US)
Blood·2025
POSTER: CT-1018 Clinical and Economic Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Newly Authorized Treatment Centers (ATCs) in the US
Clinical Lymphoma Myeloma & Leukemia·2025
CT-694: Real-World Healthcare Resource Utilization (HCRU) Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) in New Authorized Treatment Centers in the US
Clinical Lymphoma Myeloma & Leukemia·2025
CT-1018: Clinical and Economic Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Newly Authorized Treatment Centers (ATCs) in the US
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: CT-694 Real-World Healthcare Resource Utilization (HCRU) Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) in New Authorized Treatment Centers in the US
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: ABCL-1076 Estimating the Survival Impact of Not Receiving Chimeric Antigen Receptor T-cell (CAR-T) Therapy When Eligible in Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Patients in the US
Clinical Lymphoma Myeloma & Leukemia·2025
ABCL-1076: Estimating the Survival Impact of Not Receiving Chimeric Antigen Receptor T-Cell (CAR-T) Therapy When Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in the US
Clinical Lymphoma Myeloma & Leukemia·2025
Re-examining the factor structure of the Insomnia Severity Index (ISI) and defining the meaningful within-individual change (MWIC) for subjects with insomnia disorder in two phase III clinical trials of the efficacy of lemborexant
Journal of Patient-Reported Outcomes·2024· 3 citedOpen Access
Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA
Future Oncology·2024· 2 citedOpen Access
Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19–Related Hospitalization and Mortality: A Systematic Literature Review
American Journal of Therapeutics·2024· 9 citedOpen Access
516. A Systematic Literature Review Evaluating Real-World Use of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Death
Open Forum Infectious Diseases·2023· 1 citedOpen Access
Understanding the unmet needs in insomnia treatment: a systematic literature review of real-world evidence
International Journal of Neuroscience·2021· 18 citedOpen Access
306P Real-world study of treatments received and treatment satisfaction among HER2- advanced breast cancer (ABC) patients in EU3 and US
Annals of Oncology·2021
305P Real-world health-related quality of life (HRQoL) among HER2-negative (HER2-) advanced breast cancer (ABC) patients in EU3 and US
Annals of Oncology·2021
page 1 of 5Next →

Frequent Co-authors

Stacie Hudgens(7), Derek Misurski(6), Ayman Chit(5), Masatoshi Kudo(5), Renee Campbell(5), Chris T. Bauch(4), Ronda Copher(4), Edward W. Thommes(4), Amir Abbas Tahami Monfared(4), Isabelle Chabot(4), Rhys Pockett(4), John Watkins(4), Arndt Vogel(3), Shukui Qin(3), Tatsuya Yamashita(3), Lætitia Fartoux(3), Krzysztof Simon(3), Carlos López(3), Toshiyuki Tamai(3), В. В. Бредер(3)